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Abstract
Inflammatory breast cancer (IBC) is the most lethal
form of locally advanced breast cancer. We have found
that WISP3 is lost in 80% of human IBC tumors and
that it has growth- and angiogenesis-inhibitory func-
tions in breast cancer in vitro and in vivo. WISP3 is a
cysteine-rich, putatively secreted protein that belongs
to the CCN family. It contains a signal peptide at the
N-terminus and four highly conserved motifs. Here, for
the first time, we investigate the function of WISP3
protein in relationship to its structural features. We
found that WISP3 is secreted into the conditioned
media and into the lumens of normal breast ducts.
Once secreted, WISP3 was able to decrease, direct-
ly or through induction of other molecule(s), the
IGF-1–induced activation of the IGF-IR, and two of its
main downstream signaling molecules, IRS1 and ERK-
1/2, in SUM149 IBC cells. Furthermore, WISP3 contain-
ing conditioned media decreased the growth rate of
SUM149 cells. This work sheds light into the mecha-
nism of WISP3 function by demonstrating that it is
secreted and that, once in the extracellular media, it
induces a series of molecular events that leads to
modulation of IGF-IR signaling pathways and cellular
growth in IBC cells.
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Introduction
Inflammatory breast cancer (IBC) is the most lethal form of
locally advanced breast cancer [1,2]. It is also a very distinct
clinical and pathological type of carcinoma. Clinically,
patients present with what has been classically termed
‘‘peau d’orange,’’ characterized by skin thickening and
dimpling, also with nodularity, erythema, and, often, nipple
retraction [1–4]. IBC is highly angiogenic and angioinva-
sive. Clusters of malignant cells invade the dermal lym-
phatics, forming tumor emboli that likely cause the clinical
symptoms, and disseminate to distant sites [1].
In our previous work, we found that WISP3 is lost in 80%
of human IBC tumors and is a key genetic determinant of
the IBC phenotype [5]. WISP3 has growth-, invasion-, and
angiogenesis-inhibitory functions in IBC in vitro and in vivo [6].
WISP3 is a member of the CCN family of proteins, which also
includes connective tissue growth factor (CTGF), Cyr61, Nov,
WISP1, and WISP2 [7,8]. A putatively secreted protein with a
secretory signal peptide at the NH2 terminus, WISP3 contains
36 conserved cysteine residues that are organized into four
highly conserved modules: 1) a motif associated with insulin-
like growth factor binding protein (IGFBP) (GCGCCXXC); 2) a
von Willebrand type C–like motif; 3) a thrombospondin 1
module; and 4) a carboxyl-terminal domain putatively involved
in dimerization [8,9]. The role of each of these conserved
domains in the function of the CCN proteins, in general, and
of WISP3, in particular, remains to be elucidated.
IGF-I and its major receptor, IGF-IR, play an important role
in normal breast biology and in the development of breast
cancer [10–13]. A large body of work implicates the IGF family
in breast cancer progression. High concentrations of IGF-I in
serum are associated with increased mammographic density
(one of the strongest predictors of breast cancer risk), and also
reliably predict increased breast cancer risk specifically in
premenopausal women [14]. In vitro, IGF-I is a strong mitogen
for human breast cancer cells and has been found in the
epithelial and stromal component of breast cancers [13]. High
expression of IGF-IR has been demonstrated in most primary
human breast cancers when compared to normal or benign
breast tissues, and hyperactivation of IGF-IR in breast cancer
has been linked to increased radioresistance and cancer
recurrence at the primary site [13,15,16]. High levels of IRS-1,
a major signaling molecule downstream of the IGF-IR, corre-
late with tumor size and shorter disease-free survival in ER+
breast cancer patients [17,18]. Based on the protein sequence
of WISP3 and the important role of IGF signaling in breast
cancer, we hypothesized that WISP3 is secreted into the
extracellular medium and that the growth-inhibitory effect of
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WISP3 in IBC may be dependent, at least in part, on
modulation of IGF-I signaling. To test this hypothesis, we
investigated the downstream effects of WISP3 starting at the
IGF-IR receptor and signaling pathway. Here, we demon-
strate that WISP3 is a secreted protein and that, once in the
conditioned media, it can effectively modulate IGF-IR acti-
vation and its signaling cascade and the cellular growth of
IBC cells.
Materials and Methods
Cell Culture and Transfections
SUM149 cells derive from a primary IBC that has lost
WISP3 expression [6,19]. SUM149 cells and their trans-
fectants were cultured in Ham’s F-12 media supplemented
with 5% fetal bovine serum (FBS), hydrocortisone (1 mg/ml),
insulin (5 mg/ml), fungizone (2.5 mg/ml), gentamycin
(5 mg/ml), and penicillin/streptomycin (100 m/ml each), at
37jC under 10% CO2. HEK-293 cells derived from human
embryonic kidney epithelial cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% FBS.
SUM149 and HEK-293 cells were transfected with HIS
tagged (pcDNA 3.1/V5-HIS TOPO TA expression vector;
Invitrogen, Carlsbad, CA) and Flag tagged (pFlag-CMV
vector; Sigma, St. Louis, MO) full-length WISP3 cDNA, and
clonal cell lines were established as described previously [6].
Control cell lines were generated by transfecting the
SUM149 and HEK-293 cell lines with the empty vectors.
The inserts were confirmed by sequencing. Cells were
incubated in serum-free medium. WISP3 and control condi-
tioned media were collected 3 days later. The conditioned
media were cleared of cell debris by centrifugation, and
concentrated 10-fold through a Centriplus YM-10 column
(Millipore, Bedford, MA) before use.
IGF-I Stimulation
Seventy percent confluent SUM149 cells were shifted to
serum-free medium. After 24 hours of starvation, the cells
were cultured in WISP3 and control conditioned media for
24 hours. Subsequently, SUM149 cells were stimulated with
20 ng/ml human recombinant IGF-I (Upstate Biotechnology
Inc., Lake Placid, NY) for 15 minutes.
Immunoprecipitation and Western Blotting
Cells were lysed in lysis buffer composed of 50 mM Tris–
HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.25% sodium
deoxycholate, 1 mM EGTA, 1 mM Na3VO4, 1 mM PMSF,
and 1 mg/ml aprotinin. The lysates were clarified by centrifu-
gation at 14,000g for 10 minutes. A total of 500 mg of
cell lysates was incubated with 1 mg/ml anti– IGF-IR mAb
(Calbiochem, San Diego, CA) overnight at 4jC. Immune
complexes were precipitated by adding 50 ml of protein A/G
plus agarose bead slurry for 2 hours. The agarose beads
were collected and washed three times with ice-cold lysis
buffer, and resuspended in 25 ml of 2  Laemmli sample
buffer for sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE). Fifty micrograms of protein extract
was separated by SDS-PAGE and transferred onto a PVDF
membrane (Amersham Pharmacia Biotech). The precipitat-
ed IGF-IR was detected with anti– IGF-IR b subunit poly-
clonal Ab (Santa Cruz Biotechnology, Santa Cruz, CA).
Tyrosine phosphorylation of immunoprecipitated IGF-IR
was assessed with anti – phosphotyrosine mAB PY20
(Transduction Laboratories, Lexington, KY). Total IGF-IR,
phosphorylated and total IRS1, and ERK-1/2 were measured
with appropriate antibodies (Transduction Laboratories; Up-
state Biotechnology Inc.). WISP3 expression was confirmed
byWestern blot using a polyclonal anti–WISP3 antibody (gift
from Dr. Warman) and an antibody against the HIS tag
(Invitrogen). The protein bands were visualized using en-
hanced chemiluminescence (Amersham Pharmacia Biotech,
Piscataway, NJ). All experiments were repeated at least
three times and the optical density of the bands was quan-
tified by densitometry (Scio Image software for Win 95/98,
version 0.4). Statistical analysis was performed using 95%
confidence intervals for the estimates of the means. A
P value of < .05 was considered statistically significant.
Effect of WISP3 in the Proliferation of SUM149 cells
SUM149 cells were plated in 96-well tissue culture plates
at a density of 5  104 cells/ml in Ham’s F-12 media with 5%
FBS. One hundred microliters of serum-free medium was
added for 24 hours. Ten-fold concentrated WISP3 and
control conditioned media were added in the presence and
absence of IGF-I simulation as described above. MTT
reagents were added 24 hours later according to the man-
ufacturer’s protocol (Sigma), and the plate was read at a
wavelength of 595 nm. The experiment was performed in
triplicate.
Human Breast Tissues and Immunohistochemistry
WISP3 protein expression was studied by immunohisto-
chemistry in normal human breast tissues obtained from 10
reduction mammoplasty procedures. Immunohistochemical
analysis was performed by using a polyclonal anti–WISP3
antibody at 1:500 dilution with overnight incubation and
microwave antigen retrieval [20]. The detection reaction
followed the Dako Envision+ System Peroxidase kit protocol
(Dako, Carpinteria, CA). Diaminobenzidine was used as
chromogen and hematoxylin was used as counterstain.
Positive and negative controls were tumor xenografts de-
rived from cell lines shown to express high levels of WISP3
(SUM149 cell line stably transfected with WISP3) and from a
cell line that does not express WISP3 (SUM149 wild type),
respectively.
Results
WISP3 Protein Is Secreted by Human Breast Epithelial Cells
WISP3 protein contains a multimodular structure with a
secretory signal peptide at the N-terminus. To investigate
whether WISP3 is secreted by breast epithelial cells,
SUM149 IBC cells previously characterized with a loss
in WISP3 expression were stably transfected to express
full-length WISP3. Conditioned media from SUM149/
WISP3– overexpressing clones were collected and
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detected for WISP3 by Western blot analysis using a
polyclonal anti –WISP3 antibody. WISP3 protein was
detected in the media of SUM149-expressing WISP3
(SUM149/WISP3), and not in the media of empty vector–
transfected SUM149 cells (SUM149/Flag) (Figure 1A). In
order to explore these results from a different perspec-
tive, we performed transient transfections of WISP3 in
SUM149 cells using a HIS tagged full-lengthWISP3 expres-
sion vector. In this case, WISP3 protein was detected in the
conditioned media using both anti–WISP3 antibody and
anti–HIS antibody (data not shown). To specifically address
whether WISP3 would be detected in the conditioned media
of a nonmammary cell, we repeated these experiments with
the HEK293 cell line, derived from human embryonic kidney
epithelial cells.WISP3was detected in the conditionedmedia
of these cells and not in the conditioned media of the empty
vector controls (Figure 1B ).
In situ expression of WISP3 protein was determined by
immunohistochemical analysis of normal breast tissues de-
rived from reduction mammoplasty procedures. In all 10
tissues examined, WISP3 protein was expressed at low
levels in the cytoplasm of normal epithelial cells from ducts
and acini and, interestingly, was present in the luminal
secretions of ducts and lobules (Figure 2A). Xenografts
derived from wild-type SUM149 cells (WISP3) and from
SUM149/WISP3+ cells were used as negative and positive
controls, respectively (Figure 2, B and C ).
WISP3 Containing Conditioned Media Reduces IGF-I–
Induced IGF-IR Activation and Signaling Pathways
The effect of WISP3 on the activation of the IGF-I
signaling pathway was studied in SUM149 cells derived from
a primary IBC [5,6,19,21]. The activation of the IGF signaling
Figure 1. WISP3 protein is secreted and detected in the conditioned media.
(A) Western immunoblot using anti –WISP3 polyclonal antibody detects
WISP3 protein in the conditioned media of SUM149 cells transfected with
WISP3 full-length cDNA. WISP3 protein is not detected in the conditioned
media of SUM149 cells transfected with the empty vector. (B) Western
immunoblot of the conditioned media of HEK-293 cells transfected with
WISP3, detected using an anti –HIS antibody. WISP3 is not detected in the
conditioned media of the control cells.
Figure 2. In situ expression of WISP3 protein in normal breast tissues. (A) Immunohistochemical analysis of normal breast tissues using a polyclonal anti –WISP3
antibody shows that WISP3 protein is expressed at low levels in the cytoplasm of normal epithelial cells and in the luminal secretions of ducts and acini (arrows)
( 200). (B and C) Xenografts derived from wild-type SUM149 and SUM149/WISP3 cells were used as negative and positive controls, respectively ( 400).
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cascade plays a central role in breast cancer development
and progression. To investigate whether the presence of
WISP3 in the conditioned media has an effect on IGF-IR
signaling pathways in IBC cells, phosphorylation of IGF-IR,
IRS1, and ERK-1/2 was determined in wild-type SUM149
cells in the presence or absence of WISP3 in the conditioned
media. Experiments were carried out under baseline con-
ditions without addition of IGF-I and after stimulation with
IGF-I. In the presence of WISP3 in the conditioned media,
SUM149 cells exhibited decreased IGF-IR phosphorylation
(Figure 3). The effect of WISP3 in the phosphorylation of the
IGF-IR was evident in the presence of IGF-I stimulation
because WISP3 was able to ameliorate the effect of IGF-I
stimulation on the activation of the IGF-IR (Figure 3). Simi-
larly, WISP3 conditioned media decreased the IGF-I–
induced IRS1 and ERK-1/2 phosphorylation (Figures 4
and 5).
WISP3 Containing Conditioned Media Reduces the Growth
of IBC Cell Lines
After establishing that the presence of WISP3 in the
conditioned media was able to modulate IGF-I signaling
pathways, its effect on cellular proliferation was determined
in the presence and absence of IGF-I stimulation. SUM149
cells bathed in the WISP3 conditioned media had signifi-
cantly lower growth rates than the control SUM149 cells
bathed in control (WISP3-deficient) conditioned media, both
in the presence and absence of IGF-I stimulation (t test,
P < .05; Figure 6).
Discussion
We have previously demonstrated that WISP3 is lost in 80%
of IBC tumors and that it has tumor-suppressor functions in
IBC [5,6]. Studies on the SUM149 IBC cell line showed that
restoration of WISP3 expression has potent growth- and
Figure 3. WISP3 decreases IGF-I – induced phosphorylation of the IGF-IR.
(A) Western blot analysis of SUM149 cell lines bathed in WISP3+ and control
(WISP3) conditioned media. The experiment was carried out under baseline
conditions (without IGF-I) and after stimulation with 20 ng/ml IGF-I. The IGF-
IR was precipitated from 500 g of protein lysate with an anti – IGF-IR mAb
and subsequently detected by immunoblot with an anti – IGF-IR  subunit
polyclonal Ab. Tyrosine phosphorylation of immunoprecipitated IGF-IR was
assessed with an anti –phosphotyrosine mAb PY20. (B) Relative protein
levels of IGF-IR phosphorylation normalized for total IGF-IR. Blots were
scanned and the pixel intensity measured using Scn Image program. Results
are expressed as mean ± SEM of three independent experiments. (C) Quan-
titation of the differences in the percent activation of the IGF-IR. The
difference in normalized IGF-IR phosphorylation under baseline conditions
and after IGF-I stimulation was calculated for each cell line. Results were
corrected using the difference in IGF-IR phosphorylation in the absence
of IGF-I stimulation as reference. WISP3 was able to decrease the
IGF-I – induced activation of the IGF-IR (t test, P < .05).
Figure 4. WISP3 decreases IGF-I – induced phosphorylation of IRS1. (A)
Western blot analysis of SUM149 cell lines bathed in WISP3+ and control
WISP3-conditioned media. The experiment was carried out under baseline
conditions (without IGF-I) and after stimulation with IGF-I. The expression of
phosphorylated IRS1 was detected by Western blot using a polyclonal
antibody against phosphorylated IRS1. The Western blot was stripped and
probed with an antibody against total IRS1. (B) Relative protein levels of IRS1
phosphorylation normalized for total IRS1. Blots were scanned and the pixel
intensity measured. Results are expressed as mean ± SEM of three
independent experiments. (C) The differences in the percent activation of
IRS-1 were quantitated. The difference in the corrected IRS1 phosphorylation
under baseline conditions and after IGF-I stimulation was calculated for each
cell line and results were normalized using the difference in IRS1
phosphorylation in the absence of IGF-I stimulation as reference. WISP3-
rich conditioned media was able to decrease the phosphorylation of IRS-1
triggered by IGF-I (t test, P < .05).
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angiogenesis-inhibitory functions in vitro and in vivo [6].
Restoration of WISP3 resulted in a significant decrease in
anchorage-independent growth in soft agar and cellular
proliferation, as well as a drastic decrease in the invasive
capabilities of the SUM149 cells, which are highly invasive in
their wild-type state. Furthermore, restoration of WISP3
expression in SUM149 cells resulted in a biologically relevant
decrease in the level of angiogenic factors (VEGF, bFGF,
and IL-6) in the conditioned media of the cells. In vivo,
restoration of WISP3 expression in SUM149 cells caused a
drastic decrease in tumor volume and rate of tumor growth
when injected in nude mice [6]. Taken together, this body of
work had strongly supported a tumor-suppressor role for
WISP3 in mammary tumor progression. In the present study,
we sought to discover the molecular mechanisms underlying
the tumor-suppressor function of WISP3.
WISP3 belongs to the CCN family of proteins, which are
highly conserved, putatively secreted proteins with important
roles in development during chondrogenesis and skeleto-
genesis [7]. The CCN proteins have been recently also
implicated in carcinogenesis [7,22–26]. It is not well under-
stood, however, how the functions of the CCN proteins in
development relate to their role in cancer. Moreover, their
expression during tumorigenesis cannot be generalized
across different tissue types. This may be due to tissue-
specific functions of the CCN proteins, perhaps mediated by
their multimodular structure and the presence of different
affinities for binding partners and ligands in different tissues
[7]. The presence of different receptors and differential
processing of the CCN proteins (e.g., cleavage by pro-
teases) may account also for their diverse functions in
different tissues. In this paper, we focused on determining
whether WISP3 is secreted into the conditioned media and
its relationship to IGF signaling pathways.
Analysis of the protein sequence of WISP3 revealed that
it contains a signal peptide at the N-terminal region that may
participate in the secretion of the protein into the extracellular
media [7–9]. Indeed, by Western blot, using two different
specific antibodies, we were able to detect WISP3 protein in
the conditioned media of SUM149 and HEK293 cells trans-
fected with WISP3. Furthermore, consistent with these
results, by immunohistochemical analysis, WISP3 protein
was detected in the secretions accumulated in the lumens of
ducts and lobules in normal breast tissues. The fact that
WISP3 is secreted and present in the conditioned media
(thereby alluding to its stability in solution) led us to the
hypothesis that it may directly or indirectly regulate IGF
signaling.
Although the signaling pathways that are required for
the effects of IGF-I in breast cancer have not been com-
pletely elucidated, the contribution of IGF-I– induced IGF-IR
Figure 5. WISP3 decreases IGF-I – induced phosphorylation of ERK-1/2. (A)
Western blot analysis of SUM149 cell lines bathed in WISP3+ and control
(WISP3) conditioned media, under baseline conditions (without IGF-I) and
after stimulation with IGF-I. The expression of ERK-1/2 was detected by
Western blot using a polyclonal antibody against phosphorylated ERK-1/2.
The blot was stripped and probed with an antibody against -actin. (B)
Relative protein levels of ERK-1/2 phosphorylation normalized using actin.
Blots were scanned and the pixel intensity measured. Results are expressed
as mean ± SEM of three independent experiments. (C) Quantitation of the
differences in the percent activation of ERK-1/2. The difference in the
corrected ERK-1/2 phosphorylation under baseline conditions and after IGF-I
stimulation was calculated for each cell line. Results were normalized using
the difference in ERK-1/2 phosphorylation in the absence of IGF-I stimulation
as reference. WISP3-rich conditioned media ameliorated the phosphorylation
of ERK 1 and ERK 2 induced by IGF-I stimulation (t test, P < .05).
Figure 6. WISP3 decreases the growth of IBC cells. The growth of SUM149
cells was measured in the absence (WISP3) and presence of WISP3
(WISP3+) in the conditioned media under baseline conditions (no IGF-I) and
after IGF-I stimulation by an MTT assay. SUM149 cells were grown in 96-well
plates at a density of 5  104 cells/ml. Serum-starved cells were incubated
for 24 hours in the WISP3 and control conditioned media, with or without
IGF-I stimulation. Results are expressed as mean ± SEM of three
independent experiments. WISP3+ conditioned media decreases significantly
the growth of SUM149 cells (t test, P < .05 for both clones).
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activation appears to be critical in hormone-dependent and
-independent breast cancer [27–30]. IGF-I is locally re-
leased by breast cancer cells and stromal fibroblasts, and
it is involved in autocrine and paracrine stimulation of the
mammary epithelium [31]. In breast cancer cells, when IGF-I
binds IGF-IR, signaling occurs mainly through activation of
IRS-1 and RAS-dependent phosphorylation of MAP kinase
with subsequent activation of nuclear transcription factors
[32,33]. IGF-I signaling promotes cell growth, survival, and
motility of breast cancer cells, as well as resistance to
therapeutic interventions [10–12,14–18]. We hypothesized
that expression of WISP3 could result in a series of molec-
ular events that leads to the modulation of IGF-IR activation
and downstream signaling. Contributing to this hypothesis is
the fact that we have shown that WISP3 is secreted into the
media where it has the opportunity to directly or indirectly
modulate the strength of IGF signaling. Indeed, in the
presence of IGF-I, WISP3 containing conditioned media
decreased IGF-IR phosphorylation and the phosphorylation
of two main downstream IGF-IR signaling molecules, IRS1
and ERK-1/2. This inhibition was not evident under baseline
conditions, without stimulation with IGF-I. Our experiments
thus show that even relatively small concentrations of
WISP3 secreted by WISP3-transfected cells are able to
modulate, directly or indirectly, IGF-I signaling in the setting
of IGF-I stimulation.
A major growth-regulatory IGF-IR downstream pathway
that regulates breast cancer growth and survival converges
on ERK-1/2 cascade [34]. We observed a decrease in ERK-
1/2 phosphorylation by addition of WISP3 containing condi-
tioned media in the presence of IGF-I stimulation. ERK-1/2
influence chromatin remodeling and activation of gene ex-
pression, leading to enhanced cellular proliferation and
decreased apoptosis [35–37]. Specifically, ERK-1/2 have
been shown to activate the transcription of key genes
involved in cell cycle progression including cyclin D1 and
cyclin E. We have shown previously that restoration of
WISP3 expression in the highly malignant SUM149 IBC cell
line markedly decreased the levels of cyclin E and PCNA, a
reliable marker of cellular proliferation [6].
The mechanism whereby WISP3 may modulate IGF-IR
activation in the presence of IGF-I remains to be elucidated.
WISP3 contains a highly conserved motif (GCGCCXXC)
characteristic of IGFBPs, which may provide the proper
protein folding to interact with IGF-like ligands, thereby
enabling interference with IGF signaling. Although initial
studies reported that two other CCN proteins, CTGF (CTGF)
and Nov, specifically bind to IGF-I [38,39], these results
have not been subsequently built on and they remain to
be duplicated by other investigators. Whether WISP3
physically binds to IGF-I warrants further investigation, in
light of out data.
Another mechanism that may explain the modulation of
IGF-IR phosphorylation by WISP3-containing conditioned
media is the formation of a WISP3/IGF-I complex that may
bind to the IGF-IR and occupy IGF binding sites, but the
complex may be either inhibitory or may be only a weak
agonist of the receptor. In another system [40], this hypoth-
esis is supported by recent data showing that IGF-I can still
freely bind to the receptor even when complexed to a trun-
cated N-terminal fragment of IGF-binding protein 5 (mini-
IGFBP5); interestingly, the N-terminal portion of IGFBP5 has
high homology to the N-terminal portion of WISP3. Mini-
IGFBP5 binding to IGF-I resulted in incomplete inhibition of
receptor binding [40]. In a similar manner, a WISP3/IGF-I
complex might still bind to the IGF-IR but exert only a weak
agonist effect, effectively resulting in physiologic antagonism
of IGF-I action under conditions of high IGF-I stimulation.
WISP3-rich conditioned media was able to significantly
decrease the proliferation rate of IBC cells. The fact that this
effect was seen both in the presence and absence of IGF-I
simulation suggests that, in addition to interfering with
IGF-I signaling pathways, WISP3 may have IGF-indepen-
dent functions in IBC. In sum, we show that WISP3 is a
secreted protein that modulates IGF-I signaling pathways,
leading to a decrease in the growth of IBC cells.
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